LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Slēgts

SektorsVeselības aprūpe

15.44 2.86

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.02

Max

15.49

Galvenie mērījumi
By Trading Economics
Ienākumi	-130B -25B
Pārdošana	-99B 1.1T
P/E Sektora vidējais	39.974 49.888
EPS	0.21
Dividenžu ienesīgums	4.35
Peļņas marža	-2.222
Darbinieki	47,455
EBITDA	-242B 214B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+39.72% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	4.35% 2.38%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.7B 48B
Iepriekšējā atvēršanas cena	12.58
Iepriekšējā slēgšanas cena	15.44

Ziņu noskaņojums

By Acuity

100%

325 / 344 Rangs Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. maijs 08:59 UTC

Peļņas

Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit

2026. g. 29. janv. 07:11 UTC

Peļņas

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

2025. g. 19. dec. 03:32 UTC

Galvenie tirgus virzītāji

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

2025. g. 30. okt. 09:39 UTC

Peļņas

Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update

2025. g. 30. okt. 07:32 UTC

Peļņas

Takeda Posts Quarterly Net Loss, Cuts Guidance

2026. g. 13. maijs 06:57 UTC

Peļņas

Takeda Pharmaceutical 4Q Rev Y1.094T Vs. Y1.053T >4502.TO

2026. g. 13. maijs 06:54 UTC

Peļņas

Takeda Pharmaceutical 4Q Loss Y24.32B Vs. Loss Y103.2B >4502.TO

2026. g. 13. maijs 06:44 UTC

Peļņas

Takeda Pharmaceutical: FY Revenue Declined Mainly Due to Continued Generic Erosion in Neuroscience Segment >4502.TO

2026. g. 13. maijs 06:38 UTC

Peļņas

Takeda Pharmaceutical FY Net Beat Market Consensus >4502.TO

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY EPS Y121.75 Vs EPS Y68.36

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY Rev Y4.51T Vs Y4.58T

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY Pretax Pft Y260.19B Vs Pft Y175.08B

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY Net Y191.76B Vs Net Y107.93B

2026. g. 13. maijs 06:31 UTC

Peļņas

Takeda Pharmaceutical FY Oper Pft Y408.76B Vs Pft Y342.59B

2026. g. 29. janv. 06:53 UTC

Peļņas

Takeda Says Higher FY Revenue Forecast Due to Weaker Yen

2026. g. 29. janv. 06:36 UTC

Peļņas

Takeda Raises FY Revenue, Net-Profit Views

2026. g. 29. janv. 06:34 UTC

Peļņas

Takeda 3Q Net Profit Missed Y107.9B Expected in Poll of Analysts by Visible Alpha

2026. g. 29. janv. 06:33 UTC

Peļņas

Takeda Pharmaceutical 3Q Rev Y1.192T Vs. Y1.144T >4502.TO

2026. g. 29. janv. 06:32 UTC

Peļņas

Takeda Pharmaceutical 3Q Net Y103.6B Vs. Net Y23.8B >4502.TO

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Pretax Pft Y312.67B Vs Pft Y282.38B

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Oper Pft Y422.38B Vs Pft Y417.52B

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Net Y216.08B Vs Net Y211.08B

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos Rev Y3.41T Vs Y3.53T

2026. g. 29. janv. 06:30 UTC

Peļņas

Takeda Pharmaceutical 9-Mos EPS Y137.31 Vs EPS Y133.71

2025. g. 30. okt. 07:10 UTC

Peļņas

Takeda: 1H Core Business Results Were Consistent With Company's Expectations

2025. g. 30. okt. 06:50 UTC

Peļņas

Takeda 2Q Net Loss Missed Y65.2B Profit Expected in Visible Alpha Poll of Analysts

2025. g. 30. okt. 06:49 UTC

Peļņas

Takeda Pharmaceutical 2Q Rev Y1.113T Vs. Y1.176T >4502.TO

2025. g. 30. okt. 06:48 UTC

Peļņas

Takeda Pharmaceutical 2Q Loss Y11.8B Vs. Net Y92.0B >4502.TO

Salīdzinājums

Cenas izmaiņa

Takeda Pharmaceutical Co Ltd ADR Prognoze

Cenas mērķis

By TipRanks

39.72% augšup

Prognoze 12 mēnešiem

Vidējais 21 USD 39.72%

Augstākais 21 USD

Zemākais 21 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Takeda Pharmaceutical Co Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Takeda Pharmaceutical Co Ltd ADR — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.